@article{c10e054794664eabb7b1b526bfd9f1a9,
title = "Retinal vascular occlusions",
abstract = "Acute retinal vascular occlusions are common causes of visual impairment. Although both retinal artery occlusions and retinal vein occlusions are associated with increased age and cardiovascular risk factors, their pathophysiology, systemic implications, and management differ substantially. Acute management of retinal artery occlusions involves a multidisciplinary approach including neurologists with stroke expertise, whereas treatment of retinal vein occlusions is provided by ophthalmologists. Optimisation of systemic risk factors by patients{\textquoteright} primary care providers is an important component of the management of these two disorders.",
author = "Scott, {Ingrid U.} and Campochiaro, {Peter A.} and Newman, {Nancy J.} and Val{\'e}rie Biousse",
note = "Funding Information: IUS has received research support from the US National Institutes of Health (NIH) and National Eye Institute (NEI) grants 1U10EY023533–01 and 2UG1EY023533–06, and has served as a consultant for Allergan and on data safety and monitoring committees for Novartis and Thrombogenics. PAC receives research support from NIH and NEI (R01 EB 016121), an unrestricted grant to the Wilmer Eye Institute from Research to Prevent Blindness (New York, NY), Aerpio Pharmaceuticals, Asclepix Therapeutics, Genentech/Roche, Sanofi Genzyme, Graybug Vision, Novartis Pharmaceuticals Corporation, Oxford Biomedica, Perfuse, Regeneron Pharmaceuticals, and Regenexbio. PAC also serves as a consultant for Aerpio Pharmaceuticals, Allegro, Asclepix Therapeutics, Exonate, Genentech/Roche, Graybug Vision, Merck & Co, Novartis Pharmacueticals Corporation, Perfuse, and Wave Life Sciences. VB and NJN have received research support from NIH and NEI core grant P30-EY006360 (Department of Ophthalmology) and from NIH and the US Public Health Service (UL1-RR025008). NJN is a consultant for GenSight Biologics, Santhera, and Stealth Pharmaceuticals. NJN is on the data monitoring and safety committee for Quark Pharmaceuticals. VB is a consultant for GenSight Biologics and Neurophoenix. None of the authors has stocks, equity, contract of employment, or a named position on company boards. Publisher Copyright: {\textcopyright} 2020 Elsevier Ltd",
year = "2020",
month = dec,
day = "12",
doi = "10.1016/S0140-6736(20)31559-2",
language = "English (US)",
volume = "396",
pages = "1927--1940",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "10266",
}